FDA Reverses Course on Rare Blood Cancer Treatment

After surprising companies with a rejection in January, the FDA has agreed that existing trial data for a rare blood cancer therapy is sufficient for approval review.

The agency's reversal gives new hope to patients with limited treatment options.